VRTX

Over the past six months (April 2026 - October 2026), several events impacted VRTX stock. In April 2026, the FDA expanded the label for ALYFTREK and TRIKAFTA, making CFTR modulator eligibility available to approximately 95% of all U.S. CF patients. Vertex reported an 8% increase in Q1 2026 total revenue compared to Q1 2025, and completed the Biologics License Application (BLA) submission for povetacicept in IgA nephropathy, targeting a six-month priority review. In July 2026, Vertex entered an agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, aiming to expand into endocrine disease treatments, with the acquisition anticipated to close in the third quarter of 2026. In August 2026, the company reported strong Q2 2026 earnings with a 12% increase in total revenue compared to Q2 2025, leading to a 1.7% gain in VRTX shares, and raised its full-year 2026 revenue guidance to $13.1 billion to $13.2 billion. In September/October 2026, the stock price decreased by 8.02% in the month leading up to October 6, 2026. Analysts adjusted price targets, with RBC Capital raising its target to $576 and Morgan Stanley issuing a "Buy" rating. The PDUFA date for povetacicept is set for November 30th, and Q3 2026 earnings are expected on November 2, 2026.